Company / SG&A Expense
Ultragenyx Pharmaceutical Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$349.0M
FY2025
5-year range
$161.5M / $349.0M
FY2021-FY2025
Trend
+8.7%
vs FY2024
Sector context
#48 of 213
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s sg&a expense of $349M is higher than 77% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 6 consecutive years, from $100M in FY2019 to $349M in FY2025.
Based on SEC 10-K filings.
$349M in FY2025 with a 5-year CAGR of +22.3%. Top quartile in the Health Care sector.
Increased from $310M to $349M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +7.9%
- 5-Year CAGR
- +22.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 213This company $349.0M Sector average $722.3M
▼
-51.7% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s sg&a expense has grown for 6 consecutive years.
- 5-year CAGR of +22.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 8.7% year-over-year.
- Ranks #48 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $349.0M | +8.7% |
| FY2024 | $321.0M | +3.5% |
| FY2023 | $310.0M | +11.5% |
| FY2022 | $278.1M | +72.2% |
| FY2021 | $161.5M | +26.5% |
| FY2020 | $127.7M | +27.8% |
| FY2019 | $99.9M | -21.8% |
| FY2018 | $127.7M | +287.0% |
| FY2017 | $33.0M | +205.3% |
| FY2016 | $10.8M | -67.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026